"Vafidemstat (ORY-2001) is an oral small molecule that has been optimized for CNS indications and acts as a covalent inhibitor of the epigenetic enzyme Lysine-specific Demethylase-1, LSD1 (KDM1A).
Vafidemstat’s mechanism of action acts at different levels: it reduces cognitive decline and neuroinflammation, and also exerts neuroprotective effects (1). In animal models, vafidemstat not only restores memory, but reduces the exacerbated aggressiveness of SAMP8 mice, a model of accelerated aging and Alzheimer’s disease (AD), to normal levels and also reduces social avoidance and improves sociability in different rodent models.
Furthermore, vafidemstat exhibits rapid, potent, and long-lasting efficacy in several preclinical models of multiple sclerosis (MS), where it reduces neuroinflammation, modulates glial activity, shows neuroprotection, and preserves axonal integrity.
Vafidemstat has been administered to more than 400 subjects in different Phase I and II clinical trials completed or in progress, and has been safe and well tolerated."
Vafidemstat is being developed in Spain and the articles are in Spanish, I cannot put them here.
